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Abstract
Prions induce lethal neurodegeneration and consist of PrPSc, an aggregated conformer of
the cellular prion protein PrPC. Antibody-derived ligands to the globular domain of PrPC
(collectively termed GDL) are also neurotoxic. Here we show that GDL and prion infections
activate the same pathways. Firstly, both GDL and prion infection of cerebellar organotypic
cultured slices (COCS) induced the production of reactive oxygen species (ROS). Accord-
ingly, ROS scavenging, which counteracts GDL toxicity in vitro and in vivo, prolonged the
lifespan of prion-infected mice and protected prion-infected COCS from neurodegeneration.
Instead, neither glutamate receptor antagonists nor inhibitors of endoplasmic reticulum cal-
cium channels abolished neurotoxicity in either model. Secondly, antibodies against the
flexible tail (FT) of PrPC reduced neurotoxicity in both GDL-exposed and prion-infected
COCS, suggesting that the FT executes toxicity in both paradigms. Thirdly, the PERK path-
way of the unfolded protein response was activated in both models. Finally, 80% of tran-
scriptionally downregulated genes overlapped between prion-infected and GDL-treated
COCS. We conclude that GDL mimic the interaction of PrPSc with PrPC, thereby triggering
the downstream events characteristic of prion infection.
Author Summary
Prion diseases are a group of infectious, invariably fatal neurodegenerative diseases. Prog-
ress in developing therapeutics is slow, partly because animal models of prion diseases re-
quire stringent biosafety and are very slow. We recently found that treatment of cerebellar
slices with antibodies targeting the globular domain (GD ligands) of the prion protein
(PrP) is neurotoxic. Here we compared this model to prion infection, and describe striking
similarities. Both models involved the production of reactive oxygen species, and antioxi-
dants could reverse the toxicity in cerebellar slices and even prolong the survival time of
prion-infected mice. Antibodies targeting the flexible tail of PrP that prevent toxicity of
GD ligands reduced the toxicity induced by prions. Endoplasmic reticulum stress, which is
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involved in prion toxicity, is also found in GD-ligand induced neurotoxicity. Finally,
changes of gene expression were similar in both models. We conclude that prion infection
and GD ligands use converging neurotoxic pathways. Because GD ligands induce toxicity
within days rather than months and do not pose biosafety hazards, they may represent a
powerful tool for furthering our understanding of prion pathogenesis and also for the dis-
covery of antiprion drugs.
Introduction
Prion diseases are lethal infectious diseases that propagate through the conversion of the cel-
lular prion protein (PrPC) into a pathological conformer, the scrapie-associated prion pro-
tein (PrPSc) [1]. Neuronal expression of PrPC is required to mediate the neurotoxicity of
PrPSc [2] and possibly also of other protein aggregates [3], yet the pathways leading to neuro-
toxicity are largely unknown. While caspase activation, autophagy, and Ca2+ dysregulation
have been shown to occur after prion infections [4,5], ablation of Bax and caspase-12, or
overexpression of Bcl-2, does not delay incubation time of prion-infected animals [6,7]. In-
duction of autophagy, despite enhancing PrPSc clearance in vitro and in vivo, did not prolong
survival time of prion-infected mice [8]. Furthermore, excessive unfolded protein responses
(UPR) in the endoplasmic reticulum (ER) plays a significant role in the pathogenesis of
prion and other neurodegenerative diseases [9,10], yet the biochemical events emanating
from prion replication and leading to UPR induction are unknown, and it is unclear how ex-
tracellular aggregates can trigger pathology in a subcellular compartment to which they have
no direct access.
Prion infection of cerebellar organotypic cultured slices (COCS) has proven to be an ex-
traordinarily faithful and tractable model of prion disease. Prion-infected COCS replicate all
salient biochemical, histological, and pathophysiological events which occur during prion in-
fections in vivo, including PrPC-dependent prion replication [11,12], neuroinflammation with
proliferation of microglia and astrogliosis, spongiosis, and neuronal cell loss. In prion-infected
COCS, calpain inhibition confers neuroprotection without reducing prion replication, suggest-
ing that calpains are involved in neurotoxicity [13].
We have reported that exposure to antibody-derived anti-PrP ligands (full-length antibod-
ies, F(ab)1 fragments thereof, and recombinant single-chain miniantibodies) targeting the glob-
ular domain (GD) of PrPC [14] induces rapid cerebellar granular cell (CGC) degeneration in
COCS and in live mice. Since this toxic effect was also attenuated by calpain inhibitors [15], we
wondered whether the two triggers of PrP-dependent cell death, GDL and prions, might induce
similar neurotoxic cascades.
Here we report that antibodies against the flexible tail (FT) of PrPC, which prevent GD
ligand (GDL) toxicity in COCS [15], also counteracted neurotoxicity in prion-infected
COCS, suggesting a role for the FT in both models. Furthermore, GDL treatment and prion
infection triggered similar intracellular cascades including PERK activation [9] and reactive
oxygen species (ROS) production. Also, a comparative analysis of transcription in prion-in-
fected vs. GDL-exposed COCS showed extensive similarities between these two paradigms
of PrP-related toxicity. We conclude that prions and GDL share downstream pathways of
toxicity, and that in both instances the FT is the main molecular effector of prion-mediated
toxicity.
Neurotoxicity of Prions and anti-PrP Antibodies
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Results
PrPC-dependent neurodegeneration of prion-infected and GDL-exposed
COCS
Rapid neurotoxicity is elicited in COCS and in vivo by several monoclonal antibodies, single-
chain variable fragments (scFv), and F(ab)1, and F(ab)2 fragments directed against the globular
domain of PrPC [15]. We collectively termed these reagents “globular domain ligands” (GDL).
In all of the experiments described below, we used the POM1 holoantibody (67nM) as a vali-
dated paradigm of GDL-associated toxicity. Also, we have previously reported that neurode-
generation and prion replication similarly occur in COCS exposed to the three prion strains,
RML, 22L, and 139A [13]. Here, we used RML infection as an extensively characterized para-
digm of prion infection. Prion infection of COCS from tga20 transgenic mice overexpressing
PrPC [16] elicited toxicity more rapidly than in wild-type COCS [13], and was used for all ex-
periments except when otherwise indicated. As controls, pooled mouse immunoglobulins
(IgG) and non-infectious brain homogenate (NBH) were used.
First, we compared the progression of neurodegeneration in GDL-exposure vs. prion infec-
tion of COCS by measuring the area positive for neuronal-nuclear antigen (NeuN) within the
CGC layer, and by counting cells stained by propidium iodide (PI). The NeuN+ area was used
to estimate COCS viability, while the density of PI+ cells correlated with the intensity of ongo-
ing damage. A previously published time-course experiment [15] was repeated including addi-
tional time points. PI+ cells peaked at 3 days post-exposure (dpe) (S1A Fig.) and decreased
around 7–10 dpe in GDL-treated COCS. Also, significant loss of NeuN+ granule cells was de-
tectable at 3 dpe (Fig. 1A). In prion-infected COCS, we observed a peak of PI+ cells at 38 days
post infection (dpi) (S1B Fig.) and significant neuronal cell loss at 45 dpi (Fig. 1B).
GDL and prions induce pathogenic cascades that converge on ROS
induction
ROS, particularly superoxide, are causally involved in GDL toxicity [15]. We therefore asked
whether prion infection resulted in ROS production, and whether ROS scavenging might be
beneficial. We measured ROS production in live GDL-treated and RML-infected COCS by
fluorescent recording of dihydroethidium (DHE) oxidation products [17]. GDL-treated COCS
were treated with DHE at various time points between 1 h and 10 days after POM1 exposure
(Fig. 1C). Enhanced fluorescence from DHE oxidation products was observed at 4 h (67 nM).
Exposure to a fivefold higher POM1 concentration (335nM) resulted in toxicity even after 1 h.
Significantly increased fluorescence was observed in prion-infected COCS (Fig. 1D, RML “+”)
starting at 25 dpi and reached a peak at 38 dpi, but not in COCS exposed to non-infectious
brain homogenate (RML “-”).
Consistently with what we found in GDL-exposed tga20 COCS, we observed significant
ROS production, measured by DHE incorporation, in GDL-exposed COCS from wild-type
(Bl/6) mice at 7 and 14 dpe (S2A Fig.). This result provides further validation for our view that
prion related pathologies show very similar characteristics in wild-type and tga20-derived
tissues.
ROS generation was also measured by lucigenin conversion, which detects superoxide
anion radicals [18]. COCS exposed to GDL displayed increased lucigenin conversion [15],
which was quenched by diphenylene iodonium (DPI), an inhibitor of ROS-producing electron
transporters including NADPH oxidases (NOX) [15]. Similarly, we observed elevated lucigenin
conversion in prion-infected COCS at 42 dpi, indicating a strong increase in superoxide
Neurotoxicity of Prions and anti-PrP Antibodies
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Fig 1. ROS is produced in both prion-infected and GDL-exposed COCS. (A) COCS were exposed to POM1 for 8 h-10 days, and neuronal loss was
assessed by NeuN+ pixel coverage. Neuronal loss was significant at 3 dpe. Untreated slices (ut), or slices exposed to pooled IgG, were used as controls
(grey). (B) In prion-infected COCS (+) neuronal loss became significant at 45 dpi. Controls (-): exposure to non-infectious brain homogenate. Data were
analyzed using a two-tailed t-test; n = 9 biological replicates. (C—D) COCS were exposed to DHE, and the number of positive fluorescent particles was
Neurotoxicity of Prions and anti-PrP Antibodies
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production. Furthermore, addition of DPI quenched ROS production in prion-infected COCS
(Fig. 1E).
We also measured ROS production in vivo using DHE. Terminally sick RML-infected mice
were injected intraperitoneally with DHE, and DHE oxidation products were detected in brain
homogenates. Forebrains and cerebella of prion-infected mice showed higher levels of fluores-
cence than NBH-inoculated control mice (Fig. 1F).
If the superoxide burst in prion-infected COCS is a direct consequence of prion infection,
interference with prion replication should reduce ROS production. We therefore subjected
prion-infected COCS to a panel of compounds that had previously been found to antagonize
prion replication, including pentosan polysulfate (PPS), congo red (CR), and amphotericin B
(Amph). Prion-induced ROS production was reversed by treatment with PPS, CR, and Amph
(Fig. 1G lower half). Hence, ROS production is a general feature of prion toxicity downstream
of prion replication.
PPS, CR, and Amph may be effective because they intercalate with prions, or because they
activate neuroprotective pathways independently of their interactions with PrPSc. We therefore
tested the effects of PPS, CR, and Amph on GDL-treated COCS. We found that ROS produc-
tion was not reduced (Fig. 1G, upper half) and neurodegeneration was not prevented (Fig. 1H),
whereas PPS, CR, Amph counteracted neurotoxicity in prion-infected COCS [13], with PPS
being protective for at least 55 dpi (Fig. 1I). We conclude that the prionostatic properties of
these compounds, rather than any off-target effects, were indeed the proximal reason for
ROS suppression.
ROS scavengers protect against prions and GDL in vitro and in vivo
Analogously to what we observed in GDL-exposed COCS, the ROS scavengers ascorbate and
N-acetyl cysteine (NaC) completely prevented prion neurotoxicity in COCS (Fig. 2A), al-
though neither compound affected prion titers (Fig. 2B). Furthermore, ascorbate did not affect
PrPSc accumulation, total PrP levels, or processing of PrPC into the C1 fragment in prion-in-
fected COCS. Only the C2 fragment was decreased (S3A–S3D Fig.).
As previously shown for GDL toxicity, the membrane-impermeable antioxidant isoascor-
bate and the superoxide dismutase mimetic MnTBAP conferred protection against prion toxic-
ity, suggesting that the relevant ROS species are extracellular in both instances (Fig. 2A). In
contrast, the nitric oxide synthase inhibitor 1400W was ineffective in both prion-infected
(Fig. 2A) and GDL-exposed COCS [15]. These data indicate that the ROS moiety instrumental
to prion-induced neurodegeneration is superoxide, rather than nitric oxide, in both models.
We then investigated whether ascorbate would be neuroprotective over protracted periods
of time. RML-infected COCS were treated with ascorbate and harvested at various times be-
tween 45–53 dpi. Remarkably, ascorbate significantly reduced neurodegeneration of RML-
counted per 10x view field. (C) DHE conversion assays were performed at various time points between 1 h and 240 h. Data from three experiments are
represented in this graph; n = 27 biological replicates. Slices that were untreated or exposed to pooled IgG were used as controls (grey). ROS production was
detectable 4 hours after POM1 exposure and after 1 h with a higher POM1 concentration (335 nM). Here and henceforth data are presented as average ± s.
d. and were analyzed by one-way ANOVA with Dunnett’s post-hoc test unless otherwise specified (***: p<0.001; **p<0.01; *p<0.05; n.s., not significant).
Results of IgG vs POM1 at 335 nM were analyzed using a two-tailed t-test. (D) COCS were infected with RML (+) or exposed to non-infectious brain
homogenate (-). DHE conversion assays were performed at various dpi. ROS production peaked at 38 dpi. Data were analyzed using a two-tailed t-test; n =
27 biological replicates. (E) RML-infected slices (42 dpi) were harvested and analyzed for ROS production by the lucigenin assay in the presence (blue) or
absence (black) of DPI. DPI decreased superoxide-induced lucigenin conversion; n = 4 pools of 9 biological replicates. (F) DHE conversion was prominent in
the forebrains and cerebella of terminally ill scrapie-infected tga20mice. Data were analyzed using a two-tailed t-test; n = 4 mice. (G) The prion replication
antagonists, PPS, CR and Amph, suppressed ROS production in prion-infected COCS (lower half), but not in GDL-exposed COCS (upper half); n = 27
biological replicates. (H) Treatment with PPS, CR, and Amph did not reduce cell death in GDL-treated COCS; n = 9 biological replicates. Neuronal viability
was assessed here and henceforth by measuring the percentage of NeuN+ pixels (ordinate). (I) PPS treatment rescued cell death in RML-infected slices for
55dpi (red bars). Data were analyzed using a two-tailed t-test; n = 9 biological replicates.
doi:10.1371/journal.ppat.1004662.g001
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Fig 2. ROS scavengers and calpain inhibitors are beneficial to prion-infected COCS andmice. (A) Lower graph: COCS were inoculated with RML or
NBH, cultured for 21 dpi, and then treated with various compounds for 22 days. Upper graph: COCS were cultured for 14 days, incubated with POM1 and
treated with the same compounds for 10–14 days. Viability (NeuN) was normalized to COCS exposed to IgG and to non-infectious brain homogenate (upper
and lower gray dots, respectively). Calpain inhibitors (Calpeptin), antioxidants (Ascorbate, Isoascorbate, NaC), and superoxide dismutase mimetics
Neurotoxicity of Prions and anti-PrP Antibodies
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infected COCS for53 dpi (Fig. 2C). Finally, we asked whether antioxidants might be protec-
tive against prion-induced neurotoxicity in vivo. For this, we administered the enterically acti-
vated antioxidant, acetylated hydroxy tyrosol (AcHyT, 2g l-1 added to drinking water) [19], to
tga20 transgenic mice. AcHyT was previously shown to block the toxicity of GDL in vivo [15].
Tga20mice pretreated with AcHyT for 7 days were intracerebrally infected with 22L prions
(30μl, diluted 10–2) and treatment with AcHyT was continued until mice reached the criteria
for termination of the experiment. Treated animals showed a modest, but significant, life exten-
sion (Fig. 2D). Hence, AcHyT is protective in vivo against the toxicity of both prions and GDL.
We have previously shown that calpain inhibitors, but not caspase inhibitors, prevent cell
death in GDL-exposed [15] and RML-infected COCS [13] (Fig. 2A). In order to test whether
ROS signaling occurs upstream of calpain activation, we studied the effects of antioxidants on
the catabolism of fodrin, which is specifically cleaved by calpains into fragments of 145 and
150 KDa. This cleavage was blocked by calpain inhibition [13] yet was unaffected by antioxi-
dant treatment in both RML-infected and GDL-exposed COCS, indicating that ROS produc-
tion is triggered by events that are dependent on (“downstream” of) calpain activation (Fig. 2E,
F). This hierarchical sequence may not be unique to PrP-related toxicity, and other calpain ac-
tivators may plausibly also induce ROS.
Anti-excitotoxic compounds are ineffective against both GDL and prion-
induced neurotoxicity
Excitotoxicity is a potent ROS inducer [17], and PrPC can modulate NMDA and voltage-gated
calcium channels [20,21]. We therefore investigated if inhibitors of NMDA and AMPA/kainate
ionotropic glutamate receptors, or of a mitochondrial membrane permeability transition pore,
could protect COCS against GDL or prion neurotoxicity. However, none of the inhibitors were
protective in either model (Fig. 2A). Also, inhibiting ryanodine receptor-mediated calcium re-
lease from the endoplasmic reticulum (ER) with Dantrolene, was not protective (Fig. 2A).
None of the tested compounds were inherently toxic, as the viability of IgG-treated or NBH-
exposed tga20 COCS were unaffected (S4 Fig.).
Binding of the flexible tail of PrPC delays neurodegeneration in prion-
infected COCS
High-affinity ligands to the FT of PrPC such as the POM2 antibody [14] are not only innocu-
ous, but counteract the toxicity of GDL. Moreover, interstitial FT deletions prevent GDL toxici-
ty in vitro and in vivo, indicating that the FT is required to execute GDL toxicity [15]. To
determine whether the FT also mediates toxicity in prion infection, we treated prion-infected
COCS with the POM2 antibody, which recognizes the octapeptide repeats of the FT. POM2
(MnTBAP) were neuroprotective in both paradigms (red dots), whereas inhibition of AMPA, kainate receptors (CNQX), NMDA receptors (MK801), a
mitochondrial membrane permeability transition pore (methazolamide), caspases (ZVAD), and of ER calcium stores (Dantrolene), (black dots) was
ineffective; n = 9 biological replicates. The effects of compounds labeled with “†” on POM1-exposed COCS and zVAD labeled with “§” on RML-infected
COCS were reported previously [15], [13] and are reproduced here for convenience. (B) COCS were exposed to NBH (-) or to RML (+) as in (A), and
harvested at 39 dpi (n = 3). Prion titers were determined by SCEPA. No reduction in prion infectivity was observed in COCS treated with ascorbate (Asc) or
NaC (n = 3 biological replicates). (C) Prion-infected COCS were treated with Asc. Protection was discernible for53 dpi (red bars). Data were analyzed using
a two-tailed t-test; n = 9 biological replicates. (D) Survival curves of prion-infected tga20mice treated with AcHyT (median 95dpi) or vehicle (drinking water;
median 88.5dpi). AcHyT treatment increased the incubation time of prion-infected mice (p = 0.0287). Results were analyzed using a Mantel-Cox log-rank
test; n = 6 untreated mice and n = 7 AcHyT-treated mice. (E) COCS were treated with antioxidants from 21 dpi onwards (n = 3) and harvested at 40 dpi.
Cleaved α-fodrin bands (145 and 150 kDa) were quantified and normalized to GAPDH (right). None of the antioxidants suppressed the prion-induced
enhancement of α-fodrin cleavage; n = 3 biological replicates. (F) COCS were cultured for 14 days, treated with scFvPOM1 (400nM) or scFvPOM1
preincubated with recombinant PrP (1200nM) in presence of ascorbate, and harvested at 3 dpe. Cleaved α-fodrin bands (145 and 150 kDa) were quantified
and normalized to calnexin (right). Ascorbate did not suppress the GDL induced enhancement of α-fodrin cleavage; n = 3 biological replicates.
doi:10.1371/journal.ppat.1004662.g002
Neurotoxicity of Prions and anti-PrP Antibodies
PLOS Pathogens | DOI:10.1371/journal.ppat.1004662 February 24, 2015 7 / 22
prevented prion-mediated neurodegeneration in tga20 COCS, whereas equimolar amounts of
IgG had no beneficial effect (Fig. 3A). We determined prion titers by the scrapie cell-assay in end-
point format (SCEPA; [22,23], Fig. 3B), which measures the minimal concentration that still can
infect the cells and is currently the most precise measurement of infectivity in vitro. Crucially,
prion titers were not significantly affected. This finding disproves the possibility that neuroprotec-
tion was caused by reduced infectivity, and suggests that POM2 acted specifically on prion neuro-
toxicity by interfering with events triggered by the encounter of prions with their target cells.
Western blots of PK-digested samples showed that POM2 treatment led to the appearance
of PrP-immunoreactive higher-molecular weight bands (Fig. 3C), possibly representing SDS-
Fig 3. anti-FT antibody POM2 counteracts prion-induced neurotoxicity in COCS. (A) COCS prepared from tga20mice were exposed to NBH (gray) or
infected with RML prions (white), treated with pooled IgG or POM2 (335nM), and stained for NeuN at 44dpi. POM2 treatment afforded significant
neuroprotection against prion infection; n = 9 biological replicates. (B) Prion titers of slice homogenates treated as in (A) were determined by SCEPA. POM2
treatment did not significantly reduce infectivity titers in prion-infected COCS. Data points represent the log of the median infectivity dose per mg of tissue
culture (TCID50 mg
-1) ± s.d.; n = 4 biological replicates. (C) COCS homogenates were treated as in (A), digested with proteinase K, and probed with the
antibody POM1 for PrPSc. While the PrPSc bands between 18–30 kDa were somewhat decreased by POM2 treatment, there was a concomitant increase in
higher-molecular PrP-immunoreactive moieties presumably representing SDS-resistant oligomers of PrPSc. Because of the different electrophoretic patterns
of POM2-treated samples, we have opted to perform a quantification of the entire lane (right panel). POM2 treatment did not decrease the load of PK-
resistant PrPSc; n = 3 biological replicates.
doi:10.1371/journal.ppat.1004662.g003
Neurotoxicity of Prions and anti-PrP Antibodies
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stable PrPSc oligomers concomitant with reduced immunoreactivity in the 27–30 kDa range.
The total PK-resistant PrP immunoreactivity was determined by densitometric quantification
of the entire lane, and was found to be similar to that of samples that had not been exposed to
POM2. We conclude that POM2 induced a shift in the distribution of PrPSc moieties without
affecting its overall quantity. This interpretation is congruent with the results of prion titer de-
terminations (Fig. 3B).
The ER stress pathway is involved in anti-GD antibody and prion-
induced toxicity
Since ER stress has previously been shown to be involved in prion disease [9,10], we examined
the levels of phosphorylated PERK (p-PERK), phosphorylated eIF2α (p-eIF2α), and ATF4 in
both paradigms of PrPC-dependent neurotoxicity. We found a trend towards increased levels
of p-PERK, as well as significantly increased p-eIF2α and ATF4 in RML-infected COCS at 42
dpi (Fig. 4A), confirming the activation of the unfolded protein response in prion infections.
Surprisingly, we found that POM1-exposed COCS also showed increased p-PERK, p-eIF2α,
and ATF4 at 3 dpe (Fig. 4B).
To further explore this phenomenon, COCS prepared from wild-type mice were exposed to
POM1 for 7 and 14 days (S2B–S2C Fig.). At 7 dpe there was a trend towards increased p-PERK
and p-eIF2α levels, whereas ATF4 was unchanged. At 14dpe we found significantly increased
levels of p-eIF2α and ATF4, suggesting again an involvement of the PERK pathway as observed
in the tga20 COCS. This suggests that signals emanating from GDLs can propagate to the ER
and initiate a response similar to that seen in prion infections.
Prion-infected and GDL-treated COCS share transcriptional changes
The transcriptional changes occurring in COCS infected with prions and exposed to GDL were
studied by microarray hybridization. Genes were considered to be differentially expressed if
they exhibited a fold change of 2 (p value< 0.01) between RML and NBH (prion infection
paradigm) or between POM1 and IgG (GDL exposure paradigm). Upregulated and downregu-
lated genes were compared at various time points (Fig. 5A; S1–S2 Tables). To account for the
different velocity of neurodegeneration between the two models, we compared transcriptional
profiles at the time at which NeuN staining loss became significant (3 dpe for GDL vs. 45 dpi
for prion infection). The largest overlap of transcriptionally altered genes was found when
GDL-treated COCS at 3 dpe were compared to prion-infected COCS at 45 dpi. At these time
points, COCS shared 38% of all upregulated genes (Fig. 5B left; S3 Table) and 80% of all down-
regulated genes (Fig. 5B right). At the peak of ongoing cell death in both models (3 dpe for
GDL vs. 38 dpi for prion infection; S1A–S1B Fig., measured by PI incorporation), we found
that 38.4% (15/39) of upregulated genes were identical. Only one of these fifteen genes, Fosb,
has been annotated as possibly involved in the signaling initiated by activated ROS [24]. The
remaining 14 genes have been assigned to various cellular pathways, but we failed to identify
an overrepresentation of any specific pathway.
The analysis of individual genes, followed by the compilation of a list of candidates using ar-
bitrary cut-off criteria (typically fold-change and p values) may not reveal biologically impor-
tant effects on pathways. For example, a modest yet concerted increase in the activity of several
genes feeding into the same pathway may be more consequential that a strong increase of a sin-
gle member gene. We therefore set out to evaluate microarray data as predefined gene sets that
could be assigned to certain pathways. Gene set enrichment analysis (GSEA) is an important
approach to the analysis of coordinate expression changes at a pathway level [25]. Specifically,
we applied this method to our microarray data in order to specifically investigate whether the
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Fig 4. ER stress is detected in both prion-infected and GDL-exposed COCS. (A) Tga20COCS (prion-infected or NBH-exposed) were harvested at 42
dpi, and probed for p-PERK, p-eIF2α, and ATF4 by western blot. Densitometry (normalized to actin) showed a trend towards increased p-PERK (p = 0.14)
and significantly elevated p-eIF2α and ATF4 after prion infection. (B) COCS were cultured for 14 days, treated with POM1 or IgG, harvested at 3 dpe, and
probed for p-PERK, p-eIF2α and ATF4 by western blot. Densitometry (normalized to actin) revealed increased p-PERK, p-eIF2α, and ATF4. Densitometry
data were analyzed using a two-tailed t-test; n = 3 biological replicates.
doi:10.1371/journal.ppat.1004662.g004
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Fig 5. The transcriptome of RML-infected and POM1-treated COCS. (A) The number of genes upregulated or downregulated at various time points after
RML infection (left) or exposure to POM1 (right). Upregulation or downregulation was defined as>2-fold change over NBH-exposed (left) or pooled-IgG
exposed (right) COCS at the same time point. In both paradigms, the total number of differentially expressed genes increased over time. (B) Overlap of
upregulated (left) and downregulated (right) genes in RML-infected vs. POM1-exposed COCS. The two paradigms shared 80% of downregulated and 38% of
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genes constituting the TNF-ROS-CASP3 pathway are significantly regulated in a coordinated
manner in POM1 and RML-exposed COCS. Indeed, we found using GSEA, that the TNF-
ROS-CASP3 pathway indeed was significantly regulated in both POM1-exposed COCS after
3d (p = 0.037) and RML-exposed COCS after 38d (p = 0.03) and after 45d (p = 0.026). This re-
sult shows that in both paradigms genes belonging to the same ROS-dependent pathway are
activated upon exposure. Only 3 genes were downregulated at 38 dpi, one of which was down-
regulated at 3 dpe in GDL-exposed COCS.
The top 40 upregulated pathways at each time point were identified using GeneGo Meta-
Core software. When comparing POM1 at 3 dpe to prion infection at 45dpi, there was an over-
lap of 19 pathways (47.5%), while 9 out of the top 10 active pathways at 45dpi RML were
present in the top 40 of POM1 7 dpe (S4 Table).
When genes in POM1-treated COCS at different time points were compared with 45 dpi
prion-infected COCS, the correlation of genes increased with time and reached a plateau at 7
dpe POM1, with a correlation coefficient close to 0.8 (Fig. 5C). We then examined the involve-
ment of pathways from the GeneGo MetaCore database that had been described to be activated
upon prion infection, such as the ER stress response [9], ERK inhibition [26,27], autophagy
[28], CCL2 signaling [29], and TNF-ROS-casp3 [29,30]. These pathways were activated in
POM1-treated COCS in a pattern that strongly correlated with RML-infected COCS at 45dpi
(correlation value between 0.8–0.9). Scatter plots and heat maps of the genes involved in the
five signaling pathways (S5A–S5E Fig.; S6 Fig.) support this view.
To validate the regulation of genes in the microarray data, we performed nanostring analysis
for 40 genes on the same RNA preparation that was used in the microarray analysis. Differen-
tial expression of the selected genes at various time points in prion-infected and GDL-exposed
COCS (S5 Table) confirmed the results of the microarray analysis.
Discussion
Using multiple paradigms in organotypic cultures and in vivo, we show that the toxic antibody
POM1 induces largely overlapping pathogenetic cascades as bona fide prion infections. Not
only were all strategies preventing GDL-induced neurodegeneration (such as calpain inhibi-
tion, ROS scavenging and FT binding) found to be neuroprotective against prions, but com-
pounds neuroprotective against other kinds of insult (such as caspase inhibitors and glutamate
antagonists) were ineffective against both GDL and prions. Moreover, the results of transcrip-
tomic analyses are compatible with the contention of a large overlap in the downstream effec-
tors of both pathways. Besides highlighting the commonalities between GDL and prion-related
neurodegeneration (S7 Fig.), these observations set both conditions apart from other types of
neurodegenerative conditions.
Treatment of prion-infected COCS with antioxidants did not interfere with the aggregation
of PK-resistant material, as was previously shown for calpain inhibitors [13]. This adds to the
evidence that ROS scavengers and calpain inhibitors mitigate toxicity by interfering with events
triggered by prion replication. A plausible model of pathogenesis predicates that toxicity is trig-
gered by binding of either GDL or PrPSc to the globular domain of PrPC. Since inhibitors of
prion replication decreased ROS production, but did not protect from GDL toxicity and did
not reduce ROS production (Fig. 1G), we conclude that ROS production is downstream of
both prion replication and GDL binding.
upregulated genes when comparing 3dpe GDL and 45dpi RML. (C) Correlation coefficients (y-axis) of all genes and genes involved in specific signaling
pathways between POM1 exposure at different time points (x-axis) and RML exposure at 45 dpi.
doi:10.1371/journal.ppat.1004662.g005
Neurotoxicity of Prions and anti-PrP Antibodies
PLOS Pathogens | DOI:10.1371/journal.ppat.1004662 February 24, 2015 12 / 22
The modest therapeutic effect of the antioxidative therapy with AcHyt in vivo is not unex-
pected, since their involvement occurs downstream of both prion replication and calpain acti-
vation, and suggests the existence of additional pathways of toxicity that remain operational
even after scavenging ROS.
How can GDL execute such a faithful molecular mimicry of prion infection? We favor the
hypothesis that GDL and PrPSc share the same docking site on cellular PrPC. Engagement of
the latter site enacts a long-range allosteric transition of the FT, which in turn triggers the toxic
cascade. The above scenario cannot be tested directly because of the technological barriers still
hampering structural studies of PrPSc, yet it is at least compatible with the structure of the
POM1:PrPC complex, as determined by X-ray crystallography [31,32].
Solforosi et al [33] claimed that anti-PrP antibodies induced toxicity by crosslinking PrPC,
as F(ab)1 fragments were innocuous in their study. However the monovalent scFv and F(ab)1
fragments of antibody POM1 lead to toxicity in vitro and in vivo [15]. This refutes clustering of
PrPC as a cause of toxicity in the present study.
Thus far, quests for anti-prion therapeutics have been rare and mostly unsuccessful. Two
crucial reasons are the hazards associated with prion infectivity and the dearth of rapid, validat-
ed models of prion-induced toxicity. The validation of GDL as prion mimetics will help identi-
fy novel nodes in the pathogenetic cascades leading to neurodegeneration, and it is likely that
some of these nodes may represent druggable targets.
We also identified differences between the pathogenesis of GDL exposure and that of prion
infections. Firstly and most glaringly, the kinetics of GDL-induced neurodegeneration (days) is
much faster than that of experimental prion infections (months). Secondly, although GDL
function as a prion mimetic, they differ from bona fide prions by not inducing the classical
misfolding and aggregation of PrP, by failing to induce deposition of protease-resistant PrP,
and most crucially by being non-infectious. Thirdly, compounds that interfere with prion repli-
cation, such as pentosan polysulfate, do not alter the toxicity caused by GDL. All of these obser-
vations are compatible with the interpretation that GDL, while not leading to the generation of
PrPSc, trigger the same signaling pathway as prion infections.
The different speed of disease development may be taken to suggest that GDL exposure and
prion infections are fundamentally dissimilar. In our view, however, this does not contradict
the hypothesis that these two models share pathogenetic pathways. Prion infection is initiated
by trace amounts of prions within brain homogenates, with the PrPSc concentration only grad-
ually increasing upon infection of a progressively larger numbers of host cells.
The prion isolate used for a standard slice culture infection contains 7.9106 ID50 in 10 μl
[12]. Antibodies in slice culture experiments were used at 67 nM in 1 ml of medium, which cor-
responds to 4.01013 molecules. We conclude that, in the case of the antibodies, the exposure
to the bioactive principle exceeds that of prions by ca. 7 logs. This calculation is conservative
since it disregards that prion inocula were removed after exposure, and that large prion aggre-
gates are unlikely to efficiently penetrate tissues. Hence the bioactive principle in antibody
preparations exceeds that in prion infections by several orders of magnitude, which yields—in
our view—a highly plausible explanation for the difference in the kinetics
of neurodegeneration.
Finally, recent evidence suggested the involvement of the unfolded protein response in
prion-induced cell death in vivo [9]. Here, we confirm its involvement in RML and GDL-in-
duced cell death in COCS. All of the above suggests that GDL-induced neurodegeneration rep-
resents a phenocopy of bona fide prion infections. If this conjecture is correct, targeted
manipulations of the FT may be beneficial against neurotoxicity in prion infections. Indeed, we
found that binding of the FT by antibodies was neuroprotective to prion-infected slice cultures,
yet did not appreciably reduce prion titers—indicating selective suppression of the cytotoxic
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events downstream of prion replication. Therefore, binding of the FT could modify the course
of the disease by uncoupling prion replication from prion toxicity. This hypothesis remains to
be validated.
Since the GDL-induced toxicity model closely mimics multiple aspects of prion-induced
neurotoxicity of prion-induced neurotoxicity, it seems reasonable to utilize GDLs for pheno-
typic screens aimed at identifying potential antiprion therapeutics. While confirmatory coun-
terscreens will still require proof of efficacy against infectious prions, we posit that GDL
toxicity may form the basis of convenient high-throughput and non-biohazardous assays of
chemical and biological libraries.
Materials and Methods
Chemicals
All compounds were purchased from Sigma/Aldrich unless otherwise stated.
Mice
Prnpo/o;tga20+/+ (tga20) mice were on a mixed 129Sv/BL6 background [16,34]. C57BL/6 mice
were used as a wild-type mouse strain.
In vivo experiments
10-week old tga20mice were administered acetylated hydroxy tyrosol in drinking water ad libi-
tum (2 g l-1 with an approximate intake of 8 ml daily). After 7 days of treatment, mice were
anesthetized and intracerebrally inoculated with the 22L prion strain (30μl of 1% homogenate
into the temporal cortex). Prion-inoculated animals were examined every second day and eu-
thanized upon reaching pre-specified criteria for the terminal stage of disease. All prion-inocu-
lated mice developed typical signs of scrapie and prion infection was confirmed in all cases by
western blotting for protease-resistant PrPSc with the anti-PrP antibody POM1 (S8 Fig.) [14].
Organotypic brain culture preparation
Cultured organotypic cerebellar slices were prepared as previously described [11]. Briefly, cere-
bella from 10–12 day old pups were cut into 350 μm sections and kept in Gey’s balanced salt
solution (GBSS) (NaCl 8 g l–1, KCl 0.37 g l–1, Na2HPO4 0.12 g l
–1, CaCl2 2H2O 0.22 g l
–1,
KH2PO4 0.09 g l
–1, MgSO4 7H2O 0.07 g l
–1, MgCl2 6H2O 0.210 g l
–1, NaHCO3 0.227 g l
–1) sup-
plemented with the glutamate receptor antagonist kynurenic acid (1 mM) at 4°C. Six to ten
slices were then plated per Millicell-CM Biopore PTFE membrane insert (Millipore) and resid-
ual buffer was removed before placing the inserts into a cell culture plate containing “slice-cul-
ture medium” (50% vol/vol MEM, 25% vol/vol basal medium Eagle and 25% vol/vol horse
serum supplemented with 0.65% glucose (w/vol), penicillin/streptomycin and glutamax (Invi-
trogen)). Culture medium was exchanged thrice weekly and tissue cultures were kept in a hu-
midified cell culture incubator set to 37°C with 5% CO2.
Antibody treatment and prion inoculation of COCS
Antibody treatment and prion inoculations were performed as previously described [11,15,35].
Briefly, for antibody experiments, POM1 was spiked into the medium 10–14 days post-cultur-
ing, a time point at which COCS had recovered from acute phenomena associated with tissue
dissection. Fresh POM1 was provided at every medium change. Cultures were harvested for
biochemical analyses or fixed for immunocytochemical analyses at different time points.
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For prion experiments, immediately after dissection, free-floating sections were incubated
with infectious brain homogenates for 1 h at 4°C. Sections were then washed twice in 6 ml
GBSSK, and 6–10 slices were transferred onto a 6-well Millicell-CM Biopore PTFE membrane
insert (Millipore). Residual buffer was removed and inserts were placed into a 6-well culture
plate and incubated in standard slice culture medium. POM2 treatment (335nM) was initiated
after plating and re-supplied at every medium exchange.
Pharmacological treatment of COCS
For antibody experiments, drug treatment was initiated at the time of antibody addition (10–
14 days post-culturing), whereas for prion experiments, drug treatment was started at 21 dpi
when PrPSc is detectable in the cultures. Drugs were re-supplied at every medium change. As a
control, the toxicity of each compound was tested in parallel in IgG-treated slices and NBH-in-
oculated slices. The drugs and concentrations used were (+)-5-methyl-10,11-dihydro-5H-
dibenzo[a,d] cyclohepten-5,10-imine maleate (MK-801, 20 μM), 6-cyano-7-nitroquinoxaline-
2,3-dione (CNQX, 20 μM), cyclosporine A (1 μM), ascorbate (1.5 mM), isoascorbate (1.5mM),
N-(3-methyl-5-sulfamoyl-1,3,4-tiadiazol-2-ylidine)acetamide (methazolamide, 10 μM),
MnTBAP (100 μM), benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (zVAD-fmk,
40 μM), diphenyleneiodonium chloride (DPI, 5 μM), N-([3-(Aminomethyl)phenyl]methyl)-
ethanimidamide dihydrochloride (1400W, 20 μM), N-benzyloxycarbonyl-L-leucylnorleucinal
(calpeptin, 20 μM), N-acetylcystein (NaC, 1 mM), (2S,3S)-trans-epoxysuccinyl-L-leucylamido-
3-methylbutane ethyl ester (E64d, 15 mM, Bachem), 1-[(5-(p-Nitrophenyl)furfurylidene)
amino]-hydantoin sodium salt (Dantrolene, 10 μM). A summary table of the used tool com-
pounds and their biological targets are reported in S6 Table. The drugs and concentrations
used for anti-prion compounds were pentosan polysulphate (PPS, 300 ng ml-1, generously pro-
vided by Bene Pharmachem), Congo red (1 mg ml-1), and amphotericin B (4.5 mg ml-1).
Protein analysis
Inserts containing the slices were transferred to new plates containing PBS for washing (twice)
and tissue was then scraped off the membrane using 10 μl per slice of lysis buffer (0.5% sodium
deoxycholate (DOC), 0.5% Nonidet P-40 (NP-40) supplemented with complete mini protease
inhibitor cocktail (Roche) and PhosphoStop (Roche) in PBS). The harvested tissue was homog-
enized by trituration using a 30G syringe and protein concentrations were measured using the
bicinchoninic acid assay (Pierce). Samples were mixed with loading buffer (NuPAGE, Invitro-
gen) and heated at 95°C for 5 min. Equal volumes were loaded (10 μg proteins per lane) and
separated on a 12% Bis-Tris polyacrylamide gel or for higher molecular weight proteins, on a
4–12% gradient gel (NuPAGE, Invitrogen), and transferred onto a nitrocellulose membrane.
These membranes were blocked with 5% w/vol Topblock (Fluka) in TBS-T (Tris-buffered sa-
line supplemented with Tween20 (150 mMNaCl, 10 mM Tris HCl, 0.05% Tween 20 (vol/vol))
for 1 h and incubated with primary antibodies diluted in 1% Topblock in TBS-T at 4°C overnight.
After 4 washes of 15 minutes each with TBS-T, membranes were incubated with secondary anti-
body diluted in 1% Top Block in TBS-T for 1 h at RT. Primary mouse monoclonal antibodies
used were: POM1mouse IgG1 antibody raised against PrP
C (anti-PrPC; 200 ng ml–1), anti-α-
fodrin (AA6, 100 ng ml-1, Millipore), anti-GAPDH (200 ng ml-1, Millipore), anti-actin (200 ng
ml-1, Chemicon) and anti-calnexin (1:3000, Enzo Life Sciences). Secondary antibodies were
horseradish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 (1:10,000, Zymed), and goat
anti–rabbit IgG1 (1:10,000, Zymed). The following rabbit monoclonal antibodies were used: anti-
phospho PERK (Cell Signal 3179S), anti-PERK (Cell Signal 3192S), anti-phospho eIf2α (Cell
Signal 9721S), anti-eIf2α (Cell Signal 9722S), and anti-ATF4 (Cell Signal 11815S).
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Blots were developed using SuperSignal West Pico chemiluminescent substrate (Pierce) and
signals were detected using the VersaDoc system (model 3000, Bio-Rad) or Fuji. Quantification
of band intensities was performed using Quantity One 4.5.2 software (Biorad). For specific de-
tection of PrPSc, 20 μg of protein were digested with 25 μg ml-1 proteinase K in 20 μl final vol-
ume of digestion buffer (0.5% wt/vol sodium deoxycholate and 0.5% vol/vol Nonidet P-40 in
PBS) for 30 min at 37°C [11]. Loading buffer was added and samples were boiled at 95°C for
5 min to inactivate PK. PNGase F treatment was performed using a commercially available kit,
according to the manufacturer’s protocol (New England Biolabs). In brief, 10 μg of proteins
was treated with 2 μl denaturation buffer in a 20 μl sample volume and incubated for 15 min at
95°C. A reaction mixture containing 2.6 μl G7, 2.6 μl NP-40 (10%) and 0.5 μl PNGase was
added to the samples and incubated for 2h at 37°C. Samples were then boiled in presence of
loading dye, and subjected to western blot analyses.
Immunofluorescence staining and quantification
For immunofluorescence staining, organotypic slices were rinsed twice in PBS and fixed in 4%
formalin overnight at 4°C. After washing, membrane inserts were incubated in blocking buffer
(0.05% vol/vol Triton X-100 and 3% vol/vol goat serum in PBS) for 1 h and incubated with pri-
mary antibodies diluted in blocking buffer at 4°C for 3 days. The primary antibodies and con-
centrations used were mouse anti-Neuronal Nuclei (NeuN, 1 μg ml-1, Serotec), and directly
conjugated mouse anti-NeuN-Alexa488 (0.5 μg ml-1, Millipore). The primary antibodies were
detected using Alexa-conjugated secondary antibodies (3 μg ml–1, Molecular Probes). Mem-
brane inserts were washed four times with PBS and the counterstaining agent 4,6-diamidino-2-
phenylindole (DAPI) (1 μg ml–1) was added during the third washing step. Membranes were
cut and mounted with fluorescent mounting medium (Dako) on a glass slide. Images were
taken at identical exposure times with a fluorescence microscope (BX-61, Olympus) equipped
with a cooled black/white CCD camera using a 4x objective. Morphometric analyses were per-
formed to quantify the area of immunoreactivity using image analysis software analySIS vs5.0.
Viability and ROS assays
For PI incorporation, slices were rinsed with PBS and incubated for 30 min with PI (5 μg ml-1).
Live images were recorded at 5x magnification using a fluorescent microscope (Axiovert 200)
equipped with a cooled CCD camera using a 5x objective and processed using image analysis
software analySIS vs5.0.
The lucigenin conversion assay was carried out at room temperature (RT). Inserts contain-
ing 5–10 slices each were washed in PBS and lysed with a 30G syringe in Krebs-Ringer solution
supplemented with complete mini protease inhibitor cocktail (Roche). 50 μl of tissue lysate was
transferred to a 96-well white microplate containing 175 μl assay solution and 0.25 μl lucigenin
(10 mM) per well. Background measurements were performed using a chemiluminescence
reader prior to the addition of 50 μl NADPH (1 mM) to each well. Subsequently, the NADPH-
dependent signal was read and subtracted. Data are presented as relative light unit mg-1 total
protein (each bar: average of 4 inserts ± s.d.).
For DHE conversion measurements, slices were inoculated, incubated for 40 dpi, and
washed twice in GBSS. They were then incubated in GBSS containing DHE (10 μg ml-1). After
20 minutes of incubation at RT, 3 images/slice were recorded by live fluorescence microscopy
using Axiovert 200 equipped with a cooled CCD camera and using a 10x objective. Three im-
ages were recorded per slice in three individual folia of the cerebellum. Fluorescence of DHE
oxidation products was assessed by morphometry using constant thresholds.
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In vivo assessment of ROS production followed the protocol described by Murakami et al
[36]. Thirty minutes prior to euthanasia, mice were injected intraperitoneally with 200 μl DHE,
and brain tissue was homogenized in 50 mM KH2PO4, 1 mM EGTA, and 150 mM sucrose.
Fluorescence of DHE oxidation products was measured in 250 μl of 2% (w/v) homogenates
using a fluorimeter with Ex/Em 485/585nm and a cutoff of 570. Relative fluorescence units
were normalized to protein concentration.
Scrapie cell assay in endpoint format (SCEPA)
Prion-susceptible neuroblastoma cells (subclone N2aPK1) [22,23] were exposed to 300 μl cere-
bellar slice homogenates, with 6 replicates per dilution, in 96-well plates for 3 days. Cells were
subsequently split three times 1:10 every 3 days. After the cells reached confluence, 25’000 cells
from each well were filtered onto the membrane of ELISPOT plates, treated with PK (0.5 μg ml–1
for 90min at 37°C), denatured, and infected (PrPSc) cells were detected by immunocytochemistry
using alkaline phosphatase-conjugated POM1, mouse anti-PrP, and an alkaline phosphatase-
conjugated substrate kit (Bio-Rad). We performed serial ten-fold dilutions of experimental sam-
ples in cell culture medium containing healthy mouse brain homogenate. Scrapie-susceptible
PK1 cells were then exposed to dilutions of experimental samples ranging from 10–4 to 10–7
(corresponding to homogenate with a protein concentration of 10 μg ml-1 to 0.01 μg ml-1), or to
a 10-fold dilution of RML or healthy mouse brain homogenate. Samples were quantified in end-
point format by counting positive wells according to established methods [22,23].
Statistical analysis of COCS
One-way ANOVA with Tukey’s post-hoc test for multi-column comparison, or Dunnett’s
post-hoc test for comparison of all columns to a control column, were used for statistical analy-
sis of experiments involving the comparison of three or more samples. Paired Student’s t-test
was used for comparing two samples. Results are displayed as the average of replicates ± s.d.
Microarray analyses
COCS were exposed to RML/NBH or POM1/IgG for various time points; for each time point
and treatment, four cell culture inserts (n = 4) with 10 slices were used. RNA was extracted
from 10 slices per insert using TRIZOL reagent (Invitrogen, USA) and purified with RNeasy
columns (Qiagen, USA). Quality was assessed using BioAnalyzer (Agilent US). Labeled cDNA
was fragmented and hybridized to GeneChip Mouse Genome 430 2.0 Array (Affymetrix, USA)
which contains 45 000 probe sets. The data was analyzed with R/Bioconductor. Preprocessing
and normalization was done using the RMA algorithm [37] and differential expression was as-
sessed using the limma [26] package.
Nanostring
The nCounter Analysis system has been introduced previously [38]. Briefly, for each gene of in-
terest, two sequence-specific probes are designed. The probes are complementary to a 100-base
region of the target mRNA. The first probe is covalently linked to an oligonucleotide contain-
ing biotin (capture probe), and the second probe is covalently linked to a color-coded molecu-
lar tag that provided the signal (reporter probe). Forty-nine probe pairs for test genes and
control genes were contained in the nCounter CodeSet.
Neurotoxicity of Prions and anti-PrP Antibodies
PLOS Pathogens | DOI:10.1371/journal.ppat.1004662 February 24, 2015 17 / 22
Ethics statement
All mouse experiments were carried out according to Swiss law and conducted under the ap-
proval of the Animal Experimentation Committee of the Canton of Zurich (permits 200/2007,
90/2013 and 130/2008). The animal care and protocol guidelines were obtained from http://
www.blv.admin.ch/themen/tierschutz/index.html?lang = en and strictly adhered by the experi-
menters and animal facility at the institution where the experiments were performed.
Supporting Information
S1 Fig. Characterization of GDL-exposed and prion-infected COCS over time. (A-B) COCS
were exposed to POM1 for 8 h-10 days and assessed for ongoing cell death by PI incorporation
(A) PI incorporation plateaued at 1–5 dpe, Untreated slices (ut), or slices exposed to pooled
IgG, were used as controls (grey). (B) In prion-infected COCS (+), PI incorporation peaked at
38 dpi. Controls (-): exposure to non-infectious brain homogenate. Data were analyzed using a
two-tailed t-test; n = 9 biological replicates.
(TIF)
S2 Fig. ROS production and ER stress in wild-type COCS exposed to GDL. (A) wild-type
COCS exposed for 7 or 14 days to either IgG or POM1 (286 nM each) were treated with DHE,
and fluorescent particles per 10x view field were counted. At 7 and 14 dpe a significant ROS
burst was detected (n = 30 replicates). (B) COCS were cultured for 14 days, treated with POM1
or IgG, and harvested at 7 dpe. Western blots were prepared from lysates and probed for p-
PERK, PERK, p-eIF2α, eIF2α and ATF4. Densitometry (normalization to the non-phosphory-
lated form or actin for ATF4) revealed a trend towards increased p-PERK, p-eIF2α. (C) COCS
treated as in (B) were harvested at 14 dpe. p-eIF2α was significantly upregulated, and ATF4
close to statistical significance (p = 0.07). Densitometry data were analyzed using a two-tailed
t-test; n = 3 biological replicates.
(TIF)
S3 Fig. Western blot analyses of prion-infected COCS treated with ascorbate. Lanes 1–11 of
immunoblots A, B and C are reproduced from a previous study [13] for convenience. RML-in-
fected tga20 COCS were exposed to Asc starting at 21 dpi, and harvested at 39 dpi. Homoge-
nates of treated COCS were digested with proteinase K (PK) (A), left untreated (B), or treated
with PNGase F (C). Western blots were probed with POM1 to detect PrPSc, total PrP, and total
unglycosylated PrP (full-length and C1/C2 proteolytic fragments). Ascorbate and E64d only
marginally affected the C1/C2 processing of PrP (C), and did not alter the PK digestion pattern
of PrPSc (A). Sc: brain homogenate of RML-infected tga20mouse. FL: full-length PrP. (D) Den-
sitometry revealed no changes in FL or cleavage into the C1 fragment upon ascorbate treatment
in RML-infected slices. Only cleavage into the C2 fragment was reduced upon Asc treatment.
Densitometry data are presented as average ± s.d. and were analyzed by one-way ANOVA with
Dunnett post-hoc test, n = 3 biological replicates.
(TIF)
S4 Fig. Viability testing of COCS treated with various tool compounds. COCS prepared
from tga20mice were treated with pooled IgG at 67 nM for 10–14 days (upper graph) or with
non-infectious brain homogenate (NBH) for 43 days (lower graph) in the presence of the com-
pounds listed in the figure. Grey dots: no compounds were added. None of the compounds
tested affected the viability of COCS, as assessed by NeuN morphometry; n = 9 biological repli-
cates. The effects of compounds labeled with “†” on IgG-exposed COCS and zVAD labeled
with “§” on NBH-infected COCS were reported previously [15], [13] and are reproduced here
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for convenience.
(TIF)
S5 Fig. Scatter plot comparing genes of selected signaling pathways between POM1-ex-
posed and RML-infected COCS. Scatter plots comparing the expression level of genes that are
involved in specific signaling pathways found in RML-infected and POM1-exposed COCS.
The 45 days RML time point (x-axis) and the different time points of POM1 exposure (y-axis)
are represented. The correlation coefficient (cor) is indicated above each graph. These five sig-
naling pathways have been described to be activated upon prion infection. (A) Autophagy, (B)
CCL2 signaling, (C) ER stress response, (D) ERK inhibition and (E) TNF-ROS-Caspase 3 cas-
cade.
(TIF)
S6 Fig. Heat maps of the expression pattern of genes involved in the five pathways analyzed:
Autophagy, CCL2 signaling, ER stress response, ERK inhibition and the TNF-ROS-Cas-
pase 3 cascade. Downregulated (blue) and upregulated (red) genes (log2ratio) are shown for
RML vs NBH (left; purple) and POM1 vs IgG (right; green). Four replicates are depicted for
each condition. The specific pattern of upregulated and downregulated genes observed at 45
days post RML infection can also be found with increasing exposure time of POM1.
(TIF)
S7 Fig. Comparison of the pathogenetic features of prion- and GDL-induced neurotoxicity.
All investigated parameters are congruent in both models, except for the time line of toxicity
(which is explained by the large differences in the concentration of the active principle).
(TIF)
S8 Fig. PrPSc immunoblots of brain homogenates from AcHyT treated mice. Brain homoge-
nates from tga20mice infected with 22L and optionally treated with AcHyT were digested with
proteinase K and probed with the antibody POM1 for PrPSc. Negative control: non-infectious
brain homogenate (NBH).
(TIF)
S1 Table. Lists of upregulated and downregulated genes at the different time points in
RML-infected COCS. Differential expression was defined as fold change 2; p value< 0.01 vs
NBH-exposed COCS.
(XLSX)
S2 Table. Lists of upregulated and downregulated genes at different time points in POM1-
exposed COCS. Differential expression was defined as fold change 2; p value< 0.01 vs IgG
exposed COCS.
(XLSX)
S3 Table. Comparison of the gene lists. Genes upregulated and downregulated at 45dpi
(RML), 3 dpe and 7 dpe (POM1).
(XLSX)
S4 Table. Top 40 activated pathways using GeneGo MetaCore analysis. Lists of the upregu-
lated and downregulated genes at 45dpi for RML, and 3dpe and 7dpe for POM1 were up-
loaded. The top 40 pathways for POM1 at 3dpe and top 50 for POM1 at 7dpe were computed.
Nine of the top 10 of upregulated pathways at 45dpi for RML were either activated at 3dpe or
7dpe POM1.
(XLS)
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S5 Table. Comparison of values of fold change measured in microarray and nanostring.
(XLSX)
S6 Table. Summary table of the tool compounds used and their biological targets.
(DOCX)
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